{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:54:02Z","timestamp":1792713242848,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","award":["NCT03453619"],"award-info":[{"award-number":["NCT03453619"]}],"id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ekir.2023.08.033","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T12:12:27Z","timestamp":1692965547000},"page":"2284-2293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases"],"prefix":"10.1016","volume":"8","author":[{"given":"Bradley P.","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.08.033_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ekir.2016.06.005","article-title":"Complement-mediated glomerular diseases: a tale of 3 pathways","volume":"1","author":"Bomback","year":"2016","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.08.033_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.7861\/clinmed.2019-0452","article-title":"The role of complement in kidney disease","volume":"20","author":"Willows","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.ekir.2023.08.033_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.ekir.2023.08.033_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.ekir.2023.08.033_bib5","series-title":"StatPearls","article-title":"Glomerulonephritis","author":"Kazi","year":"2022"},{"key":"10.1016\/j.ekir.2023.08.033_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1053\/j.ajkd.2014.06.035","article-title":"Complement in kidney disease: core curriculum 2015","volume":"65","author":"Thurman","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.08.033_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101331","article-title":"Complement dysregulation in glomerulonephritis","volume":"45","author":"Kaartinen","year":"2019","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ekir.2023.08.033_bib8","first-page":"626","article-title":"Expanding the role of complement therapies: the case for lupus nephritis","volume":"10","author":"Li","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ekir.2023.08.033_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/2054358117753617","article-title":"Prospects for precision medicine in glomerulonephritis treatment","volume":"5","author":"Liu","year":"2018","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.ekir.2023.08.033_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy \u2013 understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2023.08.033_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fped.2020.00205","article-title":"Clinical and pathophysiological insights into immunological mediated glomerular diseases in childhood","volume":"8","author":"Mastrangelo","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ekir.2023.08.033_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12500","article-title":"Complement component C3 \u2013 The \u201cSwiss Army Knife\u201d of innate immunity and host defense","volume":"274","author":"Ricklin","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2023.08.033_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.033_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.08.033_bib15","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.08.033_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000507254","article-title":"Update on C3 glomerulopathy: a complement-mediated disease","volume":"144","author":"Caravaca-Fontan","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2023.08.033_bib17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2215\/CJN.16801221","article-title":"Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis","volume":"17","author":"Lomax-Browne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.033_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.08.033_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2023.08.033_bib20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajh.25960","article-title":"C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab","volume":"95","author":"de Castro","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ekir.2023.08.033_bib21","series-title":"APL-2 Prevents Both C3 and C5 Convertase Formation and Activity: a Potential Therapeutic for Renal Diseases","author":"Simon-Tillaux","year":"2019"},{"key":"10.1016\/j.ekir.2023.08.033_bib22","series-title":"Sampling Techniques","author":"Cochran","year":"1963"},{"key":"10.1016\/j.ekir.2023.08.033_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0009-8981(74)90357-X","article-title":"An assessment of the suitability of bromocresol green for the determination of serum albumin","volume":"53","author":"Webster","year":"1974","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ekir.2023.08.033_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1745-7599.2002.tb00119.x","article-title":"National Kidney Foundation guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"14","author":"Goolsby","year":"2002","journal-title":"J\u00a0Am Acad Nurse Pract"},{"key":"10.1016\/j.ekir.2023.08.033_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-9255-10-22","article-title":"Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration","volume":"10","author":"Kasperska-Zajac","year":"2013","journal-title":"J\u00a0Inflammm (Lond)"},{"key":"10.1016\/j.ekir.2023.08.033_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2023.08.033_bib28","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ndt\/gfab075","article-title":"Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy","volume":"37","author":"Caravaca-Fontan","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.08.033_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.08.033_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2023.08.033_bib31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.033_bib32","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.ekir.2020.07.018","article-title":"Clinical use of complement, inflammation, and fibrosis biomarkers in autoimmune glomerulonephritis","volume":"5","author":"Khalili","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.08.033_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.599974","article-title":"Deposition of the membrane attack complex in healthy and diseased human kidneys","volume":"11","author":"Koopman","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.08.033_bib34","first-page":"982","article-title":"Modern complement analysis","volume":"10","author":"Kirschfink","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.ekir.2023.08.033_bib35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.08.033_bib36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.08.033_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112944","article-title":"Monitoring ravulizumab effect on complement assays","volume":"490","author":"Willrich","year":"2021","journal-title":"J\u00a0Immunol Methods"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2023.08.033_bib38","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood-2019-122421","article-title":"Discordance between free C5 and CH50 complement assays in measuring complement C5 inhibition in patients with aHUS treated with ravulizumab","volume":"134","author":"Cataland","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2023.08.033_bib39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.08.033_bib40","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00467-018-3989-0","article-title":"Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"34","author":"Noris","year":"2019","journal-title":"Pediatr Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923014705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923014705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:48:26Z","timestamp":1762832906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923014705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2468024923014705"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.08.033","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}